Shamis & Gentile, P.A. is investigating claims on behalf of investors of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). Impacted investors are advised to contact the firm now.
The investigation concerns whether Altimmune and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. The investigation focuses on possible false and/or misleading statements made by Altimmune regarding the clinical prospects and efficacy of its lead drug candidate, pemvidutide. The period under consideration is from December 1, 2023 through June 25, 2025.
On June 26, 2025, Altimmune announced topline results from its Phase 2b improvement or complete resolution of metabolic dysfunction-associated steatohepatitis (“MASH”) trial. While the Company highlighted that the trial met its primary endpoint for MASH resolution, the same press release also revealed that the fibrosis improvement endpoint did not achieve statistical significance compared to placebo.
On this news, Altimmune’s stock price fell $5.60 per share, or approximately 52.2%, to close at $5.40 per share on June 26, 2025, erasing roughly half of the Company’s market value in a single trading day.
Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise and resources enable the firm to resolve disputes in a wide range of matters including class actions, mass torts and mass arbitrations.
